An observational study in Sepsis and Cytokine Storm, sponsored by University of Gaziantep. Completed. Per ClinicalTrials.gov, last updated 2020-01-13.
Sponsored by University of Gaziantep · Observational
Background: There is still an evident need for useful biomarkers and effective therapeutic approaches regarding the challenging management of sepsis. The aim of the study is to evaluate the effect of each Cytosorb hemoadsorption therapy course on blood levels of inflammatory biomarkers of sepsis including endocan, copeptin, interleukin-6, procalcitonin, C-reactive protein.
This observational prospective study included patients, who were diagnosed with sepsis and treated in the reanimation ICU of Gaziantep University Hospital with Cytosorb therapy between June 1st, 2016 and June 30th, 2017. Sepsis was diagnosed according to The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
Exclusion criteria of the study were: (i) cardiovascular disease, (ii) multiple traumas, (iii) malignancies, (v) incomplete clinical data.
Approval of the ethical committee (ethical committee approval number 2018/04-02) was obtained. Written informed consent was taken from each patient or their next-of-kin. Patient demographics including age, gender, and origin of sepsis were recorded. Arterial blood samples were taken from patients before and immediately after the Cytosorb therapy course.
1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.
This study's enrollment of 34 is below the median of 160 across 931 observational studies indexed under Sepsis.
Browse Sepsis studies →University of Gaziantep is the lead sponsor of 100 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This observational prospective study included patients, who were diagnosed with sepsis and treated in the reanimation ICU of Gaziantep University Hospital.
Exclusion Criteria:
Arterial blood samples were taken from patients before the Cytosorb therapy course.
Device: Cytokine aphaeresis
Arterial blood samples were taken from patients immediately after the Cytosorb therapy course.
Device: Cytokine aphaeresis
The Cytosorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Before the start of the Cytosorb therapy, adequate anti-coagulation was confirmed when target partial thromboplastin time (PTT) of 60±80 seconds, or an activated clotting time (ACT) of 180±210 seconds was achieved with systemic heparin. Antibiotics were administered after each Cytosorb therapy whenever possible.
Also known as: Cytosorb
Effect of a novel extracorporeal cytokine apheresis method on endocan levels in sepsis
The effect of each Cytosorb hemoadsorption therapy course on blood levels of endocan, an inflammatory biomarker of sepsis.
Time frame: 13 months
Effect of a novel extracorporeal cytokine apheresis method on copeptin levels in sepsis
The effect of each Cytosorb hemoadsorption therapy course on blood levels of copeptin, an inflammatory biomarker of sepsis.
Time frame: 13 months
Effect of a novel extracorporeal cytokine apheresis method on interleukin-6 levels in sepsis
The effect of each Cytosorb hemoadsorption therapy course on blood levels of interleukin-6, an inflammatory biomarker of sepsis.
Time frame: 13 months
No study locations are listed for this record.
Plan to share: No — All data included in the manuscript that will be published.
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Gaziantep